Both in 1995 and 1996 we will have seen and will see the introduction of new cytotoxic and other agents to treat the most common cancers like lung, colon and breast. Taxoids, antimetabolites, topoisomerase I inhibitors have new mechanisms of action and seem to provide hitherto unexpected therapeutic gains. Only a wider experience will tell the exact role these agents have to play, and will show if their price is indeed justified by an advantage ta the patient, as it would seem at a first glance.

Oncologie Médicale / M. Aapro, F. de Braud, G. Tommasello. - In: MÉDECINE ET HYGIÈNE. - ISSN 0025-6749. - 54:2099,(1996 Jan 10), pp. 35-37.

Oncologie Médicale

F. de Braud
Secondo
;
1996-01-10

Abstract

Both in 1995 and 1996 we will have seen and will see the introduction of new cytotoxic and other agents to treat the most common cancers like lung, colon and breast. Taxoids, antimetabolites, topoisomerase I inhibitors have new mechanisms of action and seem to provide hitherto unexpected therapeutic gains. Only a wider experience will tell the exact role these agents have to play, and will show if their price is indeed justified by an advantage ta the patient, as it would seem at a first glance.
Settore MED/06 - Oncologia Medica
Article (author)
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2434/652217
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 0
  • ???jsp.display-item.citation.isi??? ND
social impact